Transaction Advisory

Mergers and Acquisitions Sell-side

Experience and stability you can count on

When you choose Alira Health, you’ll benefit from more than two decades of in-depth expertise. Our M&A Sell-side team specializes in serving:

  • A range of companies with €5-250M valuation
  • Cross-border small- and mid-cap deals

Alira Health is a FINRA (USA) and ORIAS (EU) certified firm.

Why choose Alira Health?

As our partner, you’ll also have access to Alira Health’s in-house clinical, regulatory, and market access experts to capture the full value of your assets.

Our recent projects included an advisory role in:

  • A DNA testing company in its sale
  • A specialized contract manufacturer of precision plastic components and devices in its acquisition

Related news

M&A
Publications February 28, 2021
What’s most important when selecting a firm for your next transaction?
These are just a few of the critical factors that can help you select the right advisory firm for your next deal, whether you’re looking to license, acquire, or sell.
M&A
Publications February 24, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more download our latest TAD Infographic.
M&A Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
M&A
News November 29, 2020
We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
M&A
Publications November 1, 2020
Five Key Success Factors for Managing Transactions in Full Virtual Mode
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
M&A MedTech
Publications October 10, 2020
Q3 2020 Medical Device Contract Development and Manufacturing M&A Report
Despite the COVID-19 pandemic, M&A activity in the global CDMO industry has been exceptionally strong in 2020 with a record number of transactions completed during the third quarter alone.
M&A
News September 11, 2020
We Announce our Role as Advisor to Sagard NewGen
We are pleased to announce our role as Advisor to Sagard NewGen for the equity investment in Laboratoires Delbert. This recent capital raise of €40m supports the company’s growth(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.